Clinical Trial: A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic My

Brief Summary: An open-label phase 1 study to assess safety and efficacy of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML.

Detailed Summary:
Sponsor: Synta Pharmaceuticals Corp.

Current Primary Outcome: To assess efficacy in subjects with AML, ALL and blast-phase CML based on standard response criteria [ Time Frame: every 8 weeks ]

Original Primary Outcome: To assess efficacy in subjects with AML, ALL and blast-phase CML based on standard response criteria

Current Secondary Outcome: To characterize the safety and tolerability of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML [ Time Frame: ongoing ]

as per adverse event and serious adverse event reporting


Original Secondary Outcome: To characterize the safety and tolerability of once-weekly STA-9090 in subjects with AML, ALL and blast-phase CML

Information By: Synta Pharmaceuticals Corp.

Dates:
Date Received: August 24, 2009
Date Started: August 2009
Date Completion:
Last Updated: September 17, 2014
Last Verified: September 2014